Switch theme
Sign up to access all valuation multiples
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
2008
1.8K+
Last FY Revenue $412M
Last FY EBITDA -$183M
$8.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Caris Life Sciences achieved revenue of $412M and an EBITDA of -$183M.
Caris Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caris Life Sciences valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $412M | XXX | XXX | XXX |
| Gross Profit | XXX | $179M | XXX | XXX | XXX |
| Gross Margin | XXX | 43% | XXX | XXX | XXX |
| EBITDA | XXX | -$183M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -44% | XXX | XXX | XXX |
| EBIT | XXX | -$257M | XXX | XXX | XXX |
| EBIT Margin | XXX | -62% | XXX | XXX | XXX |
| Net Profit | XXX | -$282M | XXX | XXX | XXX |
| Net Margin | XXX | -68% | XXX | XXX | XXX |
| Net Debt | XXX | $315M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Caris Life Sciences's stock price is $29.
Caris Life Sciences has current market cap of $8.2B, and EV of $8.6B.
See Caris Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.6B | $8.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Caris Life Sciences has market cap of $8.2B and EV of $8.6B.
Caris Life Sciences's trades at 20.8x EV/Revenue multiple, and -46.9x EV/EBITDA.
Equity research analysts estimate Caris Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caris Life Sciences's P/E ratio is not available.
See valuation multiples for Caris Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV (current) | $8.6B | XXX | $8.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 20.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -46.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -33.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -29.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -33.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaris Life Sciences's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Caris Life Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caris Life Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Caris Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | 51% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -44% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 106% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caris Life Sciences acquired XXX companies to date.
Last acquisition by Caris Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Caris Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Caris Life Sciences founded? | Caris Life Sciences was founded in 2008. |
| Where is Caris Life Sciences headquartered? | Caris Life Sciences is headquartered in United States of America. |
| How many employees does Caris Life Sciences have? | As of today, Caris Life Sciences has 1.8K+ employees. |
| Who is the CEO of Caris Life Sciences? | Caris Life Sciences's CEO is Mr. David D. Halbert. |
| Is Caris Life Sciences publicy listed? | Yes, Caris Life Sciences is a public company listed on NAS. |
| What is the stock symbol of Caris Life Sciences? | Caris Life Sciences trades under CAI ticker. |
| When did Caris Life Sciences go public? | Caris Life Sciences went public in 2025. |
| Who are competitors of Caris Life Sciences? | Similar companies to Caris Life Sciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Caris Life Sciences? | Caris Life Sciences's current market cap is $8.2B |
| Is Caris Life Sciences profitable? | Yes, Caris Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
